MX2017005271A - Compuestos de nargenicina y sus usos como agentes antibacterianos. - Google Patents
Compuestos de nargenicina y sus usos como agentes antibacterianos.Info
- Publication number
- MX2017005271A MX2017005271A MX2017005271A MX2017005271A MX2017005271A MX 2017005271 A MX2017005271 A MX 2017005271A MX 2017005271 A MX2017005271 A MX 2017005271A MX 2017005271 A MX2017005271 A MX 2017005271A MX 2017005271 A MX2017005271 A MX 2017005271A
- Authority
- MX
- Mexico
- Prior art keywords
- nargenicin
- compounds
- nargenicine
- antibacterial agents
- mycobacterium tuberculosis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003242 anti bacterial agent Substances 0.000 title 1
- RBUYHCJZOXFDKG-KFIBIINQSA-N nargenicin Chemical compound O([C@@H]1[C@H](C)[C@@H](O)[C@H]2[C@]3\4O[C@H]1[C@@H]2C=C[C@@H]3C[C@@H](C(O[C@@H]([C@H](C)/C=C/4C)[C@@H](C)O)=O)OC)C(=O)C1=CC=C[N]1 RBUYHCJZOXFDKG-KFIBIINQSA-N 0.000 abstract 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 2
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- 108010013829 alpha subunit DNA polymerase III Proteins 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/06—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/089204 WO2016061772A1 (en) | 2014-10-22 | 2014-10-22 | Nargenicin compounds and uses thereof as antibacterial agents |
| PCT/US2015/056627 WO2016064982A1 (en) | 2014-10-22 | 2015-10-21 | Nargenicin compounds and uses thereof as antibacterial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017005271A true MX2017005271A (es) | 2017-08-15 |
Family
ID=55760063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005271A MX2017005271A (es) | 2014-10-22 | 2015-10-21 | Compuestos de nargenicina y sus usos como agentes antibacterianos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9944654B2 (enExample) |
| EP (1) | EP3209667B1 (enExample) |
| JP (1) | JP2017533200A (enExample) |
| KR (1) | KR20170070197A (enExample) |
| CN (1) | CN107108646A (enExample) |
| AU (1) | AU2015335992A1 (enExample) |
| BR (1) | BR112017008101A2 (enExample) |
| CA (1) | CA2964377A1 (enExample) |
| MX (1) | MX2017005271A (enExample) |
| RU (1) | RU2017117253A (enExample) |
| WO (2) | WO2016061772A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016061772A1 (en) | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Nargenicin compounds and uses thereof as antibacterial agents |
| KR102440647B1 (ko) | 2020-07-28 | 2022-09-06 | 선문대학교 산학협력단 | 나르제니신 a1 유도체를 포함하는 항혈관신생용 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4148883A (en) | 1977-08-18 | 1979-04-10 | Pfizer Inc. | Antibiotics produced by new species of nocardia |
| US4360683A (en) * | 1980-08-06 | 1982-11-23 | The Upjohn Company | Antibiotic nodusmicin derivatives |
| US4351769A (en) * | 1980-08-25 | 1982-09-28 | The Upjohn Company | Antibiotic composition of matter |
| US4448970A (en) * | 1981-02-19 | 1984-05-15 | The Upjohn Company | Nargenicin derivatives |
| US4605624A (en) * | 1982-10-21 | 1986-08-12 | Pfizer Inc. | Nocardia species capable of producing nargenicin C1 |
| US4436747A (en) | 1982-10-21 | 1984-03-13 | Pfizer Inc. | Nargenicin C1 |
| MXPA05001558A (es) | 2002-08-12 | 2005-09-08 | Pharmacia & Upjohn Co Llc | N-aril-2-oxazolidinonas y sus derivados. |
| CA2507628A1 (en) | 2002-11-28 | 2004-06-10 | Astrazeneca Ab | Oxazolidinones as antibacterial agents |
| GB0227701D0 (en) | 2002-11-28 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
| US20070197541A1 (en) | 2003-07-29 | 2007-08-23 | Oyelere Adegboyega K | Biaryl heterocyclic amines,amides, and sulfur-containing compounds and methods of making and using the same |
| KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
| JP2008500318A (ja) | 2004-05-25 | 2008-01-10 | アストラゼネカ アクチボラグ | 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン |
| WO2007133803A2 (en) | 2006-05-15 | 2007-11-22 | Rib-X Pharmaceuticals, Inc. | Treatment of mycobacterial infections |
| WO2008069619A1 (en) | 2006-12-08 | 2008-06-12 | Legochem Bioscience Ltd. | Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same |
| KR101040468B1 (ko) | 2008-02-29 | 2011-06-09 | 조선대학교산학협력단 | 새로운 노카르디아 속 균주 및 그의 발효 배양물의 용도 |
| KR101022564B1 (ko) | 2008-12-19 | 2011-03-16 | 조선대학교산학협력단 | 나르제니신을 포함하는 염증성 신경퇴행성 질환의 치료용 제약 조성물 |
| WO2011139832A2 (en) | 2010-04-28 | 2011-11-10 | Rib-X Pharmaceuticals, Inc. | Method for treating mycobacterial infections |
| KR101561964B1 (ko) | 2013-11-15 | 2015-10-20 | 한국과학기술연구원 | 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물 |
| WO2016061772A1 (en) | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Nargenicin compounds and uses thereof as antibacterial agents |
-
2014
- 2014-10-22 WO PCT/CN2014/089204 patent/WO2016061772A1/en not_active Ceased
-
2015
- 2015-10-21 MX MX2017005271A patent/MX2017005271A/es unknown
- 2015-10-21 RU RU2017117253A patent/RU2017117253A/ru not_active Application Discontinuation
- 2015-10-21 AU AU2015335992A patent/AU2015335992A1/en not_active Abandoned
- 2015-10-21 CN CN201580069971.4A patent/CN107108646A/zh active Pending
- 2015-10-21 EP EP15853228.3A patent/EP3209667B1/en active Active
- 2015-10-21 KR KR1020177013260A patent/KR20170070197A/ko not_active Withdrawn
- 2015-10-21 CA CA2964377A patent/CA2964377A1/en not_active Abandoned
- 2015-10-21 JP JP2017521550A patent/JP2017533200A/ja active Pending
- 2015-10-21 US US15/517,570 patent/US9944654B2/en active Active
- 2015-10-21 WO PCT/US2015/056627 patent/WO2016064982A1/en not_active Ceased
- 2015-10-21 BR BR112017008101A patent/BR112017008101A2/pt not_active Application Discontinuation
-
2018
- 2018-03-02 US US15/910,571 patent/US10144741B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017117253A (ru) | 2018-11-23 |
| KR20170070197A (ko) | 2017-06-21 |
| CA2964377A1 (en) | 2016-04-28 |
| JP2017533200A (ja) | 2017-11-09 |
| EP3209667B1 (en) | 2025-03-19 |
| WO2016064982A1 (en) | 2016-04-28 |
| BR112017008101A2 (pt) | 2018-02-20 |
| US10144741B2 (en) | 2018-12-04 |
| US20170305924A1 (en) | 2017-10-26 |
| EP3209667A4 (en) | 2018-06-06 |
| EP3209667A1 (en) | 2017-08-30 |
| US20180186808A1 (en) | 2018-07-05 |
| US9944654B2 (en) | 2018-04-17 |
| RU2017117253A3 (enExample) | 2019-04-16 |
| AU2015335992A1 (en) | 2017-04-20 |
| CN107108646A (zh) | 2017-08-29 |
| WO2016061772A1 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001565A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico. | |
| NI201900012A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| ECSP14013329A (es) | Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas | |
| MX2018013433A (es) | Piperidinas como inhibidores de menina. | |
| BR112017010354A2 (pt) | compostos de triazolopirimidina e usos dos mesmos | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| ECSP15028917A (es) | Compuesto heterocíclico | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| CL2016002573A1 (es) | Compuesto de ciclopropanamina y sus usos. | |
| DOP2017000066A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| MX390503B (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| UY35821A (es) | Compuesto heterocíclico | |
| SV2017005462A (es) | Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| CO2019012125A2 (es) | Inhibidores ip6k | |
| DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| CL2019002986A1 (es) | Nuevo compuesto sólido cristalino clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol. | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| MX2018009861A (es) | Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa. | |
| BR112017003231A2 (pt) | compostos heterobicíclicos e seu uso para o tratamento da tuberculose | |
| UY37502A (es) | Dinucleótido cíclico | |
| CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2017000231A1 (es) | Arilhidrazidas que contienen una fracción de 2-piridona como agentes antibacterianos selectivos |